Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors
There have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewe...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/5/1301 |
id |
doaj-6cbb63808a7b42309b9c45cad20e101e |
---|---|
record_format |
Article |
spelling |
doaj-6cbb63808a7b42309b9c45cad20e101e2020-11-25T02:34:37ZengMDPI AGJournal of Clinical Medicine2077-03832020-05-0191301130110.3390/jcm9051301Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal TumorsMasaya Iwamuro0Koji Miyahara1Chihiro Sakaguchi2Ryuta Takenaka3Sayo Kobayashi4Hirokazu Mouri5Shigetomi Tanaka6Tatsuya Toyokawa7Shouichi Tanaka8Mamoru Nishimura9Kenji Yamauchi10Takehiro Tanaka11Hiroyuki Okada12Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, JapanDepartment of Internal Medicine, Hiroshima City Hospital, Hiroshima 730-8518, JapanDepartment of Endoscopy, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, JapanDepartment of Internal Medicine, Tsuyama Chuo Hospital, Tsuyama 708-0841, JapanDepartment of Internal Medicine, Fukuyama City Hospital, Fukuyama 721-8511, JapanDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama 710-8602, JapanDepartment of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, JapanDepartment of Gastroenterology, Fukuyama Medical Center, Fukuyama 720-8520, JapanDepartment of Gastroenterology, Iwakuni Clinical Center, Iwakuni, Yamaguchi 740-8510, JapanDepartment of Internal Medicine, Okayama City Hospital, Okayama 700-0962, JapanDepartment of Gastroenterology, Mitoyo General Hospital, Kan-onji 769-1695, JapanDepartment of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, JapanDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, JapanThere have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewed the data of 142 patients with pathologically diagnosed gastric mesenchymal tumors treated at 11 institutions. We analyzed the correlation between the maximum standardized uptake value (SUVmax) evaluated using fluorodeoxyglucose-positron emission tomography (FDG-PET) and the tumor size. The correlation between the SUVmax and mitotic index was also investigated in GISTs. The SUVmax (mean ± standard deviation) was 0.5 ± 0.6 in very low-risk GISTs (<i>n</i> = 42), 2.1 ± 0.7 in low-risk GISTs (<i>n</i> = 26), 4.9 ± 0.8 in intermediate-risk GISTs (<i>n</i> = 22), 12.3 ± 0.8 in high-risk GISTs (<i>n</i> = 20), 1.0 ± 1.0 in leiomyomas (<i>n</i> = 15), 6.9 ± 1.2 in schwannomas (<i>n</i> = 10), and 3.5 in a leiomyosarcoma (<i>n</i> = 1). The SUVmax of GISTs with an undetermined risk classification was 4.2 ± 1.3 (<i>n</i> = 8). Linear associations were observed between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax of GISTs with a high mitotic index was significantly higher than that of GISTs with a low mitotic index (9.6 ± 7.6 vs. 2.4 ± 4.2). In conclusion, we observed positive correlations between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax also positively correlated with the mitotic index and risk grade in GISTs. Schwannomas showed a higher FDG uptake than GISTs and leiomyomas.https://www.mdpi.com/2077-0383/9/5/130118F-fluorodeoxyglucose-positron emission tomographymesenchymal tumorgastric neoplasmsgastrointestinal stromal tumorschwannoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Masaya Iwamuro Koji Miyahara Chihiro Sakaguchi Ryuta Takenaka Sayo Kobayashi Hirokazu Mouri Shigetomi Tanaka Tatsuya Toyokawa Shouichi Tanaka Mamoru Nishimura Kenji Yamauchi Takehiro Tanaka Hiroyuki Okada |
spellingShingle |
Masaya Iwamuro Koji Miyahara Chihiro Sakaguchi Ryuta Takenaka Sayo Kobayashi Hirokazu Mouri Shigetomi Tanaka Tatsuya Toyokawa Shouichi Tanaka Mamoru Nishimura Kenji Yamauchi Takehiro Tanaka Hiroyuki Okada Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors Journal of Clinical Medicine 18F-fluorodeoxyglucose-positron emission tomography mesenchymal tumor gastric neoplasms gastrointestinal stromal tumor schwannoma |
author_facet |
Masaya Iwamuro Koji Miyahara Chihiro Sakaguchi Ryuta Takenaka Sayo Kobayashi Hirokazu Mouri Shigetomi Tanaka Tatsuya Toyokawa Shouichi Tanaka Mamoru Nishimura Kenji Yamauchi Takehiro Tanaka Hiroyuki Okada |
author_sort |
Masaya Iwamuro |
title |
Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors |
title_short |
Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors |
title_full |
Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors |
title_fullStr |
Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors |
title_full_unstemmed |
Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors |
title_sort |
diagnostic role of 18f-fluorodeoxyglucose positron emission tomography in gastric mesenchymal tumors |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-05-01 |
description |
There have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewed the data of 142 patients with pathologically diagnosed gastric mesenchymal tumors treated at 11 institutions. We analyzed the correlation between the maximum standardized uptake value (SUVmax) evaluated using fluorodeoxyglucose-positron emission tomography (FDG-PET) and the tumor size. The correlation between the SUVmax and mitotic index was also investigated in GISTs. The SUVmax (mean ± standard deviation) was 0.5 ± 0.6 in very low-risk GISTs (<i>n</i> = 42), 2.1 ± 0.7 in low-risk GISTs (<i>n</i> = 26), 4.9 ± 0.8 in intermediate-risk GISTs (<i>n</i> = 22), 12.3 ± 0.8 in high-risk GISTs (<i>n</i> = 20), 1.0 ± 1.0 in leiomyomas (<i>n</i> = 15), 6.9 ± 1.2 in schwannomas (<i>n</i> = 10), and 3.5 in a leiomyosarcoma (<i>n</i> = 1). The SUVmax of GISTs with an undetermined risk classification was 4.2 ± 1.3 (<i>n</i> = 8). Linear associations were observed between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax of GISTs with a high mitotic index was significantly higher than that of GISTs with a low mitotic index (9.6 ± 7.6 vs. 2.4 ± 4.2). In conclusion, we observed positive correlations between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax also positively correlated with the mitotic index and risk grade in GISTs. Schwannomas showed a higher FDG uptake than GISTs and leiomyomas. |
topic |
18F-fluorodeoxyglucose-positron emission tomography mesenchymal tumor gastric neoplasms gastrointestinal stromal tumor schwannoma |
url |
https://www.mdpi.com/2077-0383/9/5/1301 |
work_keys_str_mv |
AT masayaiwamuro diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT kojimiyahara diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT chihirosakaguchi diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT ryutatakenaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT sayokobayashi diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT hirokazumouri diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT shigetomitanaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT tatsuyatoyokawa diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT shouichitanaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT mamorunishimura diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT kenjiyamauchi diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT takehirotanaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors AT hiroyukiokada diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors |
_version_ |
1724807795265503232 |